Spotlight On... WIRB-Copernicus buys Clintrax; Evotec hits a biotech milestone; and more...

Pharma contractor WIRB-Copernicus Group acquired Clintrax Global, a company that specializes in helping CROs and sponsors negotiate clinical trial contracts. Founded in 2013, Clintrax has handled negotiations in more than 65 countries, the company said, managing payments between parties in the clinical development process. WIRB-Copernicus, which offers similar services, said adding Clintrax would expand its global reach and help it compete for more clients. Release

> German service provider Evotec hit a preclinical milestone with biotech partner Padlock Therapeutics, triggering a "significant" payment in a deal that could pay out more than $13 million, the company said. News

> Biologics signed on to distribute BTG International's recently approved Vistogard in the U.S. Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.